Visual disturbances in Parkinson's disease

Practical Neurology

Volumn 6, Issue 1, 2006, Pages 28-33

  Kesler, Anat ^a   Korczyn, Amos D ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; QUETIAPINE;

APRAXIA; BLEPHAROSPASM; COLOR VISION; COLOR VISION DEFECT; ELECTROPHYSIOLOGY; EYE FIXATION; EYE MOVEMENT; EYE PAIN; EYELID MOVEMENT; GAZE; HUMAN; PARKINSON DISEASE; PATHOGENESIS; PUPIL DISEASE; QUALITY OF LIFE; REVIEW; SYMPTOM; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD; VISUAL HALLUCINATION;

EID: 32444440792     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2006.088286     Document Type: Review

References (36)

1. Hutton JT, Morris JL. Vision in Parkinson's disease. Adv Neurol 2001;86:279-88.
2. Biousse V, Skibell BC, Watts RL, et al. Ophthalmologic features of Parkinson's disease. Neurology 2004;62:177-80.
3. Hamilton SR. Neuro-ophthalmology of movement disorders. Curr Opin Ophthalmol 2000;11:403-7.
4. Bagheri H, Berlan M, Senard JM, et al. Lacrimation in Parkinson's disease. Clin Neuropharmacol 1994;17:89-91.
5. Karson CN, LeWitt PA, Calne DB, et al. Blink rates in parkinsonism. Ann Neurol 1982;12:580-3.
6. Pieri V, Diederich NJ, Raman R, et al. Decreased color discrimination and contrast sensitivity in Parkinson disease. J Neuro Sci 2000:172:7-11.
7. Dowling JE. Functional and pharmacological organization of the retina: dopamine, interplexiform cells and neuromodulation. In: Cohen B, Bodis Wollner I, eds. Vision and the brain. New York: Raven Press, 1990:1-18.
8. Regan D, Maxner C. Orientation selective visual loss in patients with Parkinson's disease. Brain 1987;110:415-32.
9. Price MJ, Feldman RG, Adelberg D, et al. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992;42:887-90.
10. Holroyd S, Currie L, Wooten GE. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:734-8.
11. Buttner T, Kuhn W, Patzold T, et al. L Dopa improves colour vision in Parkinson's disease. J Neural Transm 1994:7:13-19.
12. Buttner T Muller T, Kuhn W. Effects of apomorphine on visual functions in Parkinson's disease. J Neural Transm 2000:107:87-94.
13. Rogers GL. Functional magnetic resonance imaging (fMRI) and effects of L-Dopa on visual function in normal and amblyopic subjects. Trans Am Ophthalmol Soc 2003:101:395-410.
14. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-45.
15. Merims D, Shabtai H, Korczyn AD, et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm 2004:111:1447-53.
16. Korczyn AD. Hallucinations in Parkinson's disease. Lancet 2001:358:1031-2.
17. Nagano-Saito A, Washimi Y, Arahata Y, et al. Visual hallucination in Parkinson's disease with FDG PET. May Disord 2004:19:801-6.
18. Williams OR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's Disease: a retrospective autopsy study. Lancet Neurol 2005:4:605-10.
19. Rabey JM, Treves TA, Neufeld MY, et al. Low dose clozapine in the treatment of levodopa induced mental disturbances in Parkinson's disease. Neurology 1995:54:432-4.
20. Biousse V, Newman NJ, Caroll C, et al. Visual fields in patients with posterior Gpi pallidotomy. Neurology 1998:50:258-65
21. Leigh RJ, Zee DS. The diagnosis of central disorder of ocular motility. In: Leigh RJ, Zee DS, eds. The neurology of eye movement, 3rd edition. New York: Oxford University Press, 1999:528-32.
22. Leigh RJ, Riley DE. Eye movements in Parkinsonism: it's saccadic speed that counts. Neurology 2000:54:1018-19.
23. Repka MX, Claro MC, Loupe DN, et al. Ocular motility in Parkinson's disease. J Pediatr Ophthalmol Strabism 1996:22:144-7.
24. Rascol O, Clanet M, Montastruc JL, et al. Abnormal ocular movements in Parkinson's disease. Evidence for involvement of dopaminergic systems. Brain 1989:112:1193-214.
25. Waterston JA, Barnes GR, Grealy MA, et al. Abnormalities of smooth eye and head movement control in Parkinson disease. Ann Neurol 1996:39:749-60.
26. White OB, St Cyr JA, Tomlinson RD. Ocular motor deficits in Parkinson's disease. II. Control of the saccadic and smooth pursuit systems. Brain 1983:106:571-87.
27. Hunt LA, Sadun AA, Bassi CJ. Review of the visual system in Parkinson's disease. Optam Vis Sci 1995:72:92-9.
28. Ikeda H, Head GM, Ellis CJ. Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson's disease and a follow up study. Vision Res 1994:34:2629-38.
29. Bandini F, Pierantozzi M, Bodis-Wollner I. Parkinson's disease changes the balance of onset and offset visual responses: an evoked potential study. Clin Neurophysiol 2001:112:976-83.
30. Bodis-Wollner I, Yahr ML, Mylin L, et al. Dopaminergic deficiency and delayed visual evoked potential in humans. Ann Neurol 1982:11:478-83.
31. Bodis-Wollner I, Tagliati M. The visual system in Parkinson's disease. Adv Neurol 1993:60:390-4.
32. Rodnitzky RL. Visual dysfunction in Parkinson's disease. Clin Neurosci 1998:5:102-6.
33. Gottlob I, Schneider E, Heider W, et al. Alteration of visual evoked potentials and electroretinograms in Parkinson's disease. Electroencephalogr Clin Neurophysiol 1987:66:349-57.
34. Micieli G, Tassorelli C, Martignoni F, et al. Disordered pupil reactivity in Parkinson's disease. Clin Auton Res 1991:1:55-8.
35. Korczyn AD. Autonomic nervous system disturbances in Parkinson's disease. Adv Neurol 1990:53:463-8.
36. Micieli G, Tosi P, Marcheselli S, et al. Autonomic dysfunction in Parkinson's disease. Neurol Sci 2003:1:S32-34.